發(fā)布時(shí)間：2018-02-24 09:46

  本文關(guān)鍵詞： 沙格列汀 二甲雙胍 復(fù)方制劑 療效 安全性　出處：《中國(guó)糖尿病雜志》2017年01期 　論文類(lèi)型：期刊論文

【摘要】：沙格列汀與二甲雙胍聯(lián)用覆蓋T2DM多重病理生理缺陷,不僅降低糖尿病患者血糖,且不增加低血糖風(fēng)險(xiǎn),兼減重效應(yīng)。UKPDS研究證實(shí),二甲雙胍有心血管保護(hù)作用,SAVOR研究明確了沙格列汀的心血管安全性。國(guó)內(nèi)即將上市的沙格列汀二甲雙胍緩釋片復(fù)方制劑可實(shí)現(xiàn)每日一次口服給藥,提高患者依從性,帶來(lái)更多的臨床獲益。依據(jù)國(guó)內(nèi)外最新指南,該復(fù)方制劑可作為HbA_1c≥7.5%的新診斷T2DM患者,或二甲雙胍單藥治療血糖未達(dá)標(biāo)患者的治療選擇之一。
[Abstract]:Combined use of salgletine and metformin to cover multiple pathophysiological defects in T2DM not only reduced blood glucose but also did not increase the risk of hypoglycemia in diabetic patients. Metformin has cardiovascular protective effect. The study of SAVOR has confirmed the cardiovascular safety of salgletine. The compound preparation of salglutin sustained-release tablets, which will be available in China, can be administered orally once a day and improve the compliance of patients. According to the latest guidelines at home and abroad, this compound preparation can be used as one of the treatment options for newly diagnosed T2DM patients with HbA_1c 鈮，

本文編號(hào)：1529792